DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant

- Pivotal Phase 3 data presented in ASCO oral session, simultaneously published in The Lancet and granted Priority Review by the U.S. FDA this week - The Phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study conducted...

from PR Newswire: http://bit.ly/2KlScaQ